WO2008053250A2 - Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser - Google Patents

Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser Download PDF

Info

Publication number
WO2008053250A2
WO2008053250A2 PCT/GB2007/050666 GB2007050666W WO2008053250A2 WO 2008053250 A2 WO2008053250 A2 WO 2008053250A2 GB 2007050666 W GB2007050666 W GB 2007050666W WO 2008053250 A2 WO2008053250 A2 WO 2008053250A2
Authority
WO
WIPO (PCT)
Prior art keywords
drug
hydrofluoroalkane
suspension
pharmaceutically acceptable
stabiliser
Prior art date
Application number
PCT/GB2007/050666
Other languages
French (fr)
Other versions
WO2008053250A3 (en
Inventor
Ian Walter Kellaway
Kevin Taylor
Bildad Kimani Nyambura
Original Assignee
School Of Pharmacy, University Of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by School Of Pharmacy, University Of London filed Critical School Of Pharmacy, University Of London
Priority to US12/447,560 priority Critical patent/US20100143268A1/en
Priority to JP2009533962A priority patent/JP2010508256A/en
Priority to EP07824878A priority patent/EP2089008B1/en
Priority to ES07824878T priority patent/ES2373389T3/en
Priority to DK07824878.8T priority patent/DK2089008T3/en
Priority to AT07824878T priority patent/ATE516800T1/en
Publication of WO2008053250A2 publication Critical patent/WO2008053250A2/en
Publication of WO2008053250A3 publication Critical patent/WO2008053250A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to compositions which are suitable for administering to humans or animals via pressurised metered dose inhalers.
  • the compositions include a propellant in which an active is suspended, which further includes a suspension stabiliser.
  • Pressurised metered dose inhalers allow delivery of a predetermined dose of a composition from the aerosol -like device.
  • a propellant un der pressure in the form of a liquid.
  • the propellant suspends the active agent during delivery from the device, and evaporates to an extent prior to the active reaching the throat.
  • the active is generally insoluble in the propellant liquid and as such is in the form of suspended particles in the liquid.
  • the active In order for a dose expelled from the pMDI to contain the appropriate dose of active ingredient, it is crucial for the active to be stably suspended in the liquid. It has been suggested that the partic les may be coated with surfactant so as to stabilise the suspension. However many of the traditional and pharmaceutically acceptable surfactants in use today are insoluble in the liquids used as propellants in pMDIs. It has been necessary to use a co -solvent which is miscible with the propellant and dissolves the surfactant. It would be desirable to avoid the need for co-solvents and avoid the presence of such surfactants.
  • WO-A-9640089 discloses a pharmaceutical composition for aerosol delivery comprising a medicament, a halogenated alkane propellant and a biocompatible C- I 6+ " unsaturated vegetable oil and a method for preparing such compositions. Unwanted aggregation of the medicament is prevented without the use of surfactants, protective colloids or cosolvents by the incorporation of the vegetable oil.
  • EP-A-1166774 discloses the use of a flavouring oil in a pharmaceutical aerosol formulation.
  • the flavouring oil acts as a lubricant of the valve of the dispersing device used to administer said formulation.
  • the flavouring oil is a volatile oil and also acts as a penetration enhancer.
  • An example is peppermint oil which is used in conjunction with ethanol, the carrier of an un specified active.
  • EP-A-0372777 discloses a pharmaceutical composition for aerosol delivery e.g. for inhalation, comprising a medicament, 1 ,1 ,1 ,2 -tetrafluoroethane (HFA 134a), a surface active agent and at least one compound having higher polarity than
  • the examples use ethanol and n -pentane as the additive and all the worked examples include also surfactant.
  • EP-A-1219293 discloses a pharmaceutical composition for aerosol de livery comprising a medicament, a hydrofluoroalkane, a cosolvent and a low volatility component.
  • the low volatility component increases the mean median, aerodynamic diameter of the aerosol particles on activation of the inhaler.
  • the cosolvent is generally ethanol or a glycol.
  • the low volatility component may be a vegetable oil, a fatty acid, a polyethylene glycol or glycerol.
  • US5502076 discloses the use of vitamin E acetate, C 3-linked triesters, glycerin, t-butanol, and transesterified oil/polyethylene glycols as effective dispersing agents for use with hydrofluoroalkanes, for use in metered -dose inhalers.
  • US-A-6123924 discloses a pressurised aerosol inhalation composition comprising a liquefied hydrofluoroalkane, a powdered medicament dispersible to form a suspension in the liquefied hydrofluoroalkane and polyvinylpyrrolidone as stabiliser.
  • the compositions additionally comprise polyethoxylated valve lubricants and flavouring excipients such as peppermint oil and menthol and generally also ethanol and /or propanol which increase the solubility of the polymer.
  • WO-A-911 1173 discloses a pressurised aerosol composition
  • a pressurised aerosol composition comprising a liquefied hydrofluorocarbon propellant containing substantially no non - hydrofluorocarbon solvent, having dispersed therein a m edicament and a fluorinated surfactant.
  • WO-A-9104011 discloses a self-propelling, powder dispensing aerosol comprising medicament coated with a non -perfluorinated surface -active dispersing agent suspended in an aerosol propellant in which the non -perfluorinated surface- active dispersing agent is substantially insoluble.
  • the dispersing agent may be a vegetable oil such as corn, olive, cotton seed or sunflower seed oil.
  • compositions which are in haled either through the nose or through the mouth.
  • essential oils may well have utility in compositions which are in haled, either through the nose or through the mouth.
  • a new metered dose inhaler containing a composition comprising a pharmaceutically acceptable hydrofluoroalkane liquid propellant, a drug to be delivered to the lung which is insoluble in the propellant and is in particulate form suspen ded in the propellant and an effective drug suspending amount of a pharmaceutically acceptable essential oil which is miscible with the propellant.
  • a pharmaceutically acceptable essential oil to stabilise in a p MDI a suspension of a particulate drug in a pharmaceutically acceptable hydrofluoroalkane liquid in which the drug is insoluble and with which the essential oil is miscible.
  • a combination of a pharmaceutically acceptable hydrofluoroalkane liquid, a drug and a pharmaceutically acceptable essential oil in the manufacture of a composition for administration to the lung of an animal subject via inhalation, wherein the drug is in particulate form in the composition, the particles of drug are suspended in the hydrofluoroalkane liquid, the essential oil is miscible with the hydrofluoroalkane and the suspension is stabilised by the essential oil.
  • the hydrofluoroalkane liquid i n the composition is preferably selected from hydrofluoroalkane 227 and134a.
  • the non -toxic essential oil used in the composition of the invention may generally be defined as a liquid which is substantially immiscible with water at room temperature, and is a liquid at room temperature.
  • Essential oils are volatile oils comprised mainly of mono - and sesquiterpene hydrocarbons and their oxygen derivatives. They are products of distillation, expression or solvent extraction of plants, including flowers, lea ves, wood and grasses, or they may be produced synthetically. They comply with the European monograph for Essential Oils.
  • the oil may be a single compound, or may be a mixture of compounds.
  • essential oils is intended to include the following examples, though the invention is not limited to these examples: allspice berry, amber essence, anise seed, arnica, balsam of peru, basil, bay, bay leaf, bergamot, bois de rose (rosewood), cajeput, calendula (marigold pot), white camphor, caraway seed, car damon, carrot seed, cedarwood, celery, chamomile, chamomile, cinnamon, citronella, clary sage, clovebud, coriander, cumin, cypress, eucalyptus, fennel, Siberian fir needle, frankincense(olibanum oil), garlic, rose geranium, ginger, grapefruit, hyssop, jasmine, jojoba, juniper berry, lavender, lemon, lemongrass, lime, marjoram, mentol, mugwort, mullein flower, myrrh gum, bigarade neroli, nutme
  • beta- caryophyllene 3-phenylpropenaldehyde; mixed geranial and neral; 3,7-dimethyl-6- octenal; 3,7-dimethyl-6-octen-l-ol; 4-allylanisole; ethyl-3 phenylpropenoic acid; 3 - ethoxy-4-hydroxybenzaldehyde; 1 ,8 -cineole; 4-allyl-2 methoxyphenol; 3,7,11 - trimethyl-2,6,10-dodecatrien-1-ol; 1 ,3,3-trimethylbicyclo[2.2.1]heptan -2-ol; 1 , 3,3- trimethylbicyclo[2.2.1]heptan -2-one; trans-3,7-dimethyl-2,6-octadien-1 -ol; trans-3,7- dimethyl-2,6-octadien-1-yl acetate; 3-methyl-2-(2 pentenyl)-2-cyclopenten
  • the oil used in the invention must be substantially immiscible with water, it is generally found to be useful for the oil to have some amphiphilic properties.
  • the oil may comprise a relatively hydrophobic portion and a relatively hydrophilic portion.
  • the hydrophobic portion generally comprises one or more C 6- 24 -alkyl groups, preferably a single alkyl group, more preferably a C ⁇ -i ⁇ alkyl group.
  • a relatively hyd rophilic portion may, for instance, comprise a ketonic or aldehydic carbonyl group. Oils which have some amphiphilic character are believed to tend to localise at the surface of the particles of pharmaceutically active compound and act to stabilise their suspension in the hydrofluoroalkane.
  • the oil is selected from citral, menthol, eucalyptus oil, cinnamaldehyde and cineole. Mixtures may be used.
  • the essential oils acts as a suspending agent. Its effect is to inhibit agglomeration of the drug particles in the suspension in liquefied HFA. The effect may be observed for instance by determining the particle size of suspended particles formed in the absence and in the presence of the essential oil. It may be possible to avoid the presence of all other additives which could affect the suspension, such as liquids like alcohols, glycols and esters, or surfactants or co - propellants.
  • the lever of other liquids is less than 20% by volume of the composition preferably less than 5% or less than 1 % by volume.
  • the volume ratio of essential oil to hydrofluoroalkane is in the range 1 to 10,000 to 10,000 to 1 , preferably in the range 1 to 100 to 1 to 2.
  • the amount of essential oil may depend on the particle size and solids concentration of the active particles as well as the nature of the oil, the HFA and the active. It may be determined by the person skilled in the art.
  • the invention has two areas of utility, for two different classes of pharmaceutical active.
  • the invention is of utility for formulating active compounds which are water soluble, that is have a water solubility of at least 0.1 mg/ml at room temperature.
  • active compounds which are water soluble, that is have a water solubility of at least 0.1 mg/ml at room temperature.
  • solid protectants e.g. lyoprotectants, such as a sugar.
  • Sugars used as a lyoprotectant are generally selected from lactose and trehalose, but other sugars may also be used.
  • the particles which are suspended in the liquid comprise both the protectant and the active.
  • the particles themselves may be formed using the process of freeze -drying water-in-oil emulsions containing the pharmaceutical active and protectant in aqueous soluti on in the dispersed phase followed by washing.
  • more conventional processing technologies for producing particles with desired characteristics e.g. milling, precipitation, crystallization, polymerization, spray - drying, supercritical fluid p rocessing, solvent diffusion/evaporation, etc. may be employed.
  • a water -soluble active is, for instance, a peptide or a protein, for instance an enzyme or a hormone, or a nucleic acid, for instance siRNA and DNA, such as ge ne therapy vectors and gene vaccines.
  • the invention has been found to be of particular utility for formulating insulin. It is of particular utility for formulating proteins where the active particles comprise a protectant, preferably lactose.
  • the particles suspended in the composition have mean particle size in the range 0.01 to 20 ⁇ m preferably in the range 0.2 to 10 ⁇ m. Particles which are too large are deposited in the throat rather than reaching the lung. Particles which are too small may be exhaled.
  • the other type of active for which the invention has particular utility is for formulating relatively water-insoluble compounds.
  • Such compounds may be defined as having water solubility less then 0.1 mg/ml at room tern perature.
  • Such compounds should preferably have solubility in the stabiliser of at least 0.5 mg/ml at room temperature.
  • Such compounds have solubility in the hydrofluoroalkane less than 0.1 mg/ml.
  • the relatively water-insoluble actives are often selected from steroids, corticosteroids, bronchodilators, beta -2 agonists, antibiotics, anti -microbials, antivirals, muscarinic antagonists, phosphodiesterase inhibitors and antihistamines.
  • the invention is of utility for formulating an active selected from, for instance, salmeterol, terbutaline, cromolyns, beclometas one, budesonide, mometasone, ciclesonide, triamcinolone, fluticasone, rofleponide, salbutamol, formeterol, oxitropium, roflumilast and pharmaceutically acceptable salts and esters of any of these.
  • the composition should have a concentration of active se lected according to the therapeutic activity thereof and the volume dosage of composition usefully administered by the pMDI.
  • a suitable unit dose administered via a pMDI contains 30 to 100 ⁇ l liquid composition.
  • a suitable pharmaceutical active content f or such a dose is in the range 0.001 to 10 ⁇ mg/100 ⁇ l, depending on the activity of the pharmaceutical agent, the age and weight of the patient etc.
  • the person skilled in the art is generally able to select suitable concentrations for the invention.
  • the invention allows stable compositions to be created having concentrations of up to 10 ⁇ mg/100 ⁇ l active, allowing carefully controlled dosages to be delivered.
  • a dose of composition administered per actuation of a pMDI contains in the range of 30 to 600 ⁇ g of pharmaceutical active per actuation.
  • the essential oil may be used as the sole suspending agent in the composition. Its stabilising properties may allow other conventional components such as fixed oils (vegetable oils), alcohols, glycols, surfactants and polymers to be omitted from the compositions.
  • the essential oil often prevents agglomeration of the drug particles to a sufficient degree to be used alone.
  • the composition is substantially free of fixed oils, although small qu antities may present for instance as diluent for essential oil or as residue from an active as supplied.
  • the level of fixed oils is less than 5% by volume, more preferably less than 1 % by volume.
  • polymer such as PVP is used as an additio nal suspending agent it is generally present in an amount in the range 0.01 to 5% w/v, preferably 0.1 to 2% w/v.
  • compositions are preferably substantially free of lower alcohols and gl ycols (C 2 -6), for instance containing less than 10% by volume, preferably less than 5% by volume, for instance less than 1 % by volume. It is also possible, by the use of essential oils in the invention, to avoid the inclusion of surfactants. However for some actives, the use of pharmaceutically acceptable surfactants may be provide additional control over the particle size or drug. For instance there may be surfactant used in the composition in an amount of 0.01 to 5% w/v, preferably less than 1 % w/v. M ost preferably the composition is substantially free of surfactant, that is there is less than 0.01 % w/v surfactant present.
  • the active is dissolved into the suspension stabiliser to form a solution and the solution is added to the hydrofluoroalkane.
  • the non-solvent for the therapeutic active i.e. the hydrofluoroalkane
  • drug precipitate is formed.
  • the presence of the suspension stabiliser maintains the particles of the precipitate in suspension.
  • the pharmaceutical active is insoluble in the suspension stabiliser
  • particles of the desired size for the final product are dispersed into the Ii quid suspension stabiliser, to form a stable suspension, and the suspension is then added to hydrofluoroalkane to form the stable final composition.
  • the suspended particles may contain protectant which are generally sugars such as lactose and trehalose, and other appropriate excipients as well as active.
  • the present invention also encompasses novel compositions a) a pressurised composition for inhalation comprising a pharmaceutically acceptable hydrofluoroalkane liquid propellant, insul in in suspended particulate form and cineole and b) a pressurised composition inhalation for comprising a pharmaceutically acceptable hydrofluoroalkane liquid propellant, a steroid or corticosteroid for delivery to the lung and citral.
  • Figure 1 shows the particle size determination results on products of Example 1 ;
  • Figure 2 shows the effect on the aerolisation results by increasing oil concentration for products of the invention as described in Example 1 ;
  • Figure 3 shows the variation of aerolisation results upon changing the concentration of active in the process as described in Example 1 ;
  • Figures 4 and 5 show the resul ts of Example 2.
  • INSULIN-BASED COMPOSITIONS WITH CINEOLE STABILISER Insulin nanoparticles were prepared using an emulsion template method. 80 mg insulin and 20 mg lactose were dissolved into 1 ml of 0.1 M HCI. 2 g lecithin (phosphatidylcholin e surfactant) was weighed separately and dissolved in 7 ml chloroform to form the oily phase. The aqueous phase was added dropwise into the oil phase while homogenizing at low speed (10,000 rpm) followed by high speed homogenization (24,000 rpm) for 5 min. The emulsion formed was immediately snap-frozen using liquid nitrogen to immobilise the disperse phase.
  • lecithin phosphatidylcholin e surfactant
  • the frozen emulsions were transferred into a vacuum proof glass jar (Girovac Ltd., North Walsham, Norfolk, UK) and attached to the freeze -drier (Drywin ner 110, Heto- Holten A/S, Gydevang, Denmark) set at -110 0 C. Freeze-drying was performed for a minimum of 12 h to remove water from the frozen microscopic aqueous droplets. Following the freeze -drying stage, dry matter containing nanoparticles covered with surfactant (lecithin) was obtained. This was washed to remove lecithin by the following steps.
  • the dry matter was suspended in 0.5% v/v triethylamine (TEA) in dichloromethane in which insulin and lactose were insoluble while lecithin was freely soluble, therefore preserving the structure of the nanoparticles.
  • TAA triethylamine
  • These nanoparticles were separated from free surfactant by centrifugation (3K30 Refrigerated centrifuge, Sigma Laborzentrifuges GmbH, Osterode am Harz, Germany).
  • the sedimentation conditions were 17 ,000 rpm at 25 0 C. 50 ml Oakridge Teflon (Trade Mark) centrifuge tubes (Nalge -Nunc Inc., Rochester, NY, USA) were selected for centrifugation owing to their excellent solvent compatibility and ease of nanoparticle collection from the non -stick surface.
  • the solvent plus surfactants were decanted and the sediments which comprised nanoparticles were collected. The washing process was repeated twice.
  • the sediment of nanoparticles was suspended in 5 ml of dichloromethane and 0.25 ml cineole was added. The suspen sion formed was vortexed to ensure homogeneity.
  • Dichloromethane was removed by evaporation under vacuum using a Rotavapor® (B ⁇ chi, Switzerland) set at 35 0 C for 5 min.
  • a paste of nanoparticles moistened by cineole was obtained which was subsequently cold fi Ned, oil placed in vials and cooled to a temperature below the boiling point of HFA 134a, then chilled (condensed) HFA 134a was added and the vial closed.
  • the solid concentration (i.e. insulin plus lactose) of the filled vials was 1 % w/w.
  • an anti-foaming agent to the emulsion (glyceryl monoleate) was investigated with an objective of reducing the size of the nanoparticles. This was achieved by dissolving 1 g of glyceryl monoleate and 2 g of lecithin in 7 ml of chloroform to form the oily ph ase. However, all other processing conditions were maintained as described above.
  • the formulation was subsequently assessed within two days of manufacture to determine the particle size using photon correlation spectroscopy (PCS), and the morphology of th e particles was examined using scanning electron microscopy (SEM).
  • PCS photon correlation spectroscopy
  • SEM scanning electron microscopy
  • the formulations were also assessed for the integrity of insulin using gel permeation chromatography (GPC), high performance liquid chromatography (HPLC), circular dichroism and fluorescen ce spectroscopy.
  • MSLI multistage liquid impinger
  • the MSLI separates aerosol particles in a moving airstream on the basis of their aerodynamic diameters and allows an estimate of the fine particle fraction (FPF) of the aerosol emitted from a pMDI.
  • FPF refers to the fraction of the inhaler output that has an aerodynamic diameter less than about 1.7 ⁇ m. This represents the fraction of the drug dose that can reach the alveolar region of the lung where systemic drug absorption occurs.
  • the PCS results for the product produced without glyceryl monooleate indicate that the nanoparticles have a z -average diameter of around 550 nm with a narrow size distribution (polydispersity index 0.084 as determined by the PCS device).
  • the SEM micrographs showed that the nanoparticles were substantially spherical in shape.
  • the GPC and HPLC chromatograms, compared to standard insulin, show t hat the products are very similar to standard insulin, suggesting that insulin is not chemically degraded during the formulation process.
  • Far-UV circular dichroism spectra indicate that the secondary structures of insulin are retained after processing.
  • Th ere is no significant difference ( p ⁇ 0.05) between spectra, and the secondary structure composition of unprocessed (control material) and processed (from the nanoparticles after delivery from the pMDI) were comparable.
  • Control insulin, insulin from the n anoparticles after freeze -drying and insulin recovered following actuation of the pMDI formulation produced similar near -UV CD spectra, with a peak at around 275 nm. This indicates retention of tertiary structures of insulin after processing. This is con firmed from fluorescence spectra of insulin samples after delivery from the pMDI, and before and after de naturation with 6M guanidine hydrochloride, as compared with standard insulin under the same conditions.
  • Figure 2 shows the effect of cineole concentration (ml/batch; a batch is equivalent to 100mg nanoparticle (insulin plus lactose) formulation in 1 Og HFA 134a) on FPF and throat deposition of nanoparticles.
  • Figure 3 shows the FPF and throat deposition of pMDI formulations containing 1 %, 2.5% and 5% concentration of insulin nanoparticles in HFA 134a each with cineole at a level of 0.25 ml/batch of 10 g HFA) .
  • the size of the nanoparticles was reduced to z -average diameter of around 347 nm when glyceryl monoleate was added to the oil phase during the production of 1 % formulations of nanoparticles. These nanoparticles were used to formulate the optimized pMDI formulation.
  • the emitted dose per actuation was approximately 0.55 mg total solids that yield 0.44 +/ - 0.04 mg/actuation insulin, based on the insulin content in the nanoparticles being 80%.
  • the formulation had around 45% insulin weight of emitted dose (ex-actuator) delivered as FPF.
  • SX was weighed and dissolved in a known amount of chilled citral.
  • SX has an aqueous solubility of 66 -81 ⁇ g/ml (Tong, HY, et al, Pharm. Res. (2001 ) 18, 852 - 858), i.e. it is not "water-soluble" in the terms of the present specification.
  • the solution (see below for amount/concentration) was added dropwise in 10 ml of chilled HFA 134a while homogenizing at a lo w speed (10,000 rpm).
  • a 63 ⁇ l actuation metering valve (Valois DF60 MK42; Valois, France) was immediately crimped onto the pMDI canister (using manual bottle crimper 3000, Aero -Tech Laboratory Equipment Company, USA).
  • the amount of citral used was varied f rom 2 to 33% v/v while the SX concentration in the formulation was varied from 0.05 to 0.9% w/v based on the entire formulation.
  • the pMDI vials were sonicated (XB6 Grant Instruments Ltd., UK) for approximately 1 min and the stability of the suspension was assessed visually.
  • the amount of SX in the upper and lower stage of the twin impinger was assessed using a high performance liquid chromatography (HPLC) set with the conditions outlined in Table 1.
  • HPLC high performance liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A formulation suitable for delivery from a pressurised metered dose inhaler comprises a hydrofl uoroalkane liquid, which is pharmaceutically acceptable, for instance HFA 134a or HFA 227, a drug to be delivered to the lung which is insoluble in the hydrofluoroalkane, the drug being in particulate form in the composition, further containing a suspension stabiliser which is a non -toxic essential oil miscible with the hydrofluoroalkane liquid at room temperature. The essential oil is preferably one having some amphiphilic property, such as a ketone or aldehyde compound. Insulin may be formulated for inhalation.

Description

FORMULATIONS FOR DELIVERY VIA PRESSURISED METERED DOSE
INHALERS
The present invention relates to compositions which are suitable for administering to humans or animals via pressurised metered dose inhalers. The compositions include a propellant in which an active is suspended, which further includes a suspension stabiliser.
Pressurised metered dose inhalers (pMDIs) allow delivery of a predetermined dose of a composition from the aerosol -like device. Inside the pressurised container is a propellant, un der pressure in the form of a liquid. The propellant suspends the active agent during delivery from the device, and evaporates to an extent prior to the active reaching the throat. The active is generally insoluble in the propellant liquid and as such is in the form of suspended particles in the liquid.
In order for a dose expelled from the pMDI to contain the appropriate dose of active ingredient, it is crucial for the active to be stably suspended in the liquid. It has been suggested that the partic les may be coated with surfactant so as to stabilise the suspension. However many of the traditional and pharmaceutically acceptable surfactants in use today are insoluble in the liquids used as propellants in pMDIs. It has been necessary to use a co -solvent which is miscible with the propellant and dissolves the surfactant. It would be desirable to avoid the need for co-solvents and avoid the presence of such surfactants.
WO-A-9640089 discloses a pharmaceutical composition for aerosol delivery comprising a medicament, a halogenated alkane propellant and a biocompatible C-I6+" unsaturated vegetable oil and a method for preparing such compositions. Unwanted aggregation of the medicament is prevented without the use of surfactants, protective colloids or cosolvents by the incorporation of the vegetable oil.
EP-A-1166774 discloses the use of a flavouring oil in a pharmaceutical aerosol formulation. The flavouring oil, as well as masking unpleasant tastes of sublingual compositions, acts as a lubricant of the valve of the dispersing device used to administer said formulation. Preferably the flavouring oil is a volatile oil and also acts as a penetration enhancer. An example is peppermint oil which is used in conjunction with ethanol, the carrier of an un specified active.
EP-A-0372777 discloses a pharmaceutical composition for aerosol delivery e.g. for inhalation, comprising a medicament, 1 ,1 ,1 ,2 -tetrafluoroethane (HFA 134a), a surface active agent and at least one compound having higher polarity than
1 ,1 ,1 ,2-tetrafluoroethane such as an alcohol, a hydrocarbon or another propellant.
The examples use ethanol and n -pentane as the additive and all the worked examples include also surfactant.
EP-A-1219293 discloses a pharmaceutical composition for aerosol de livery comprising a medicament, a hydrofluoroalkane, a cosolvent and a low volatility component. The low volatility component increases the mean median, aerodynamic diameter of the aerosol particles on activation of the inhaler. The cosolvent is generally ethanol or a glycol. The low volatility component may be a vegetable oil, a fatty acid, a polyethylene glycol or glycerol. US5502076 discloses the use of vitamin E acetate, C 3-linked triesters, glycerin, t-butanol, and transesterified oil/polyethylene glycols as effective dispersing agents for use with hydrofluoroalkanes, for use in metered -dose inhalers. US-A-6123924 discloses a pressurised aerosol inhalation composition comprising a liquefied hydrofluoroalkane, a powdered medicament dispersible to form a suspension in the liquefied hydrofluoroalkane and polyvinylpyrrolidone as stabiliser. The compositions additionally comprise polyethoxylated valve lubricants and flavouring excipients such as peppermint oil and menthol and generally also ethanol and /or propanol which increase the solubility of the polymer.
WO-A-911 1173 discloses a pressurised aerosol composition comprising a liquefied hydrofluorocarbon propellant containing substantially no non - hydrofluorocarbon solvent, having dispersed therein a m edicament and a fluorinated surfactant.
WO-A-9104011 discloses a self-propelling, powder dispensing aerosol comprising medicament coated with a non -perfluorinated surface -active dispersing agent suspended in an aerosol propellant in which the non -perfluorinated surface- active dispersing agent is substantially insoluble. The dispersing agent may be a vegetable oil such as corn, olive, cotton seed or sunflower seed oil.
Pharmaceutically acceptable propellants used in pMDIs are hydrofluoroalkane 227 and 134 a. Many essential oils are useful as pharmaceutically acceptable excipients for a range of pharmaceutical compositions. Essential oils themselves may have useful therapeutic properties. Essential oils may well have utility in compositions which are in haled, either through the nose or through the mouth. However, to the inventors' knowledge the use of essential oils as a suspension stabiliser for a drug in a pressurised metered dose inhaler has not been described.
There is provided according to one asp ect of the invention a new metered dose inhaler containing a composition comprising a pharmaceutically acceptable hydrofluoroalkane liquid propellant, a drug to be delivered to the lung which is insoluble in the propellant and is in particulate form suspen ded in the propellant and an effective drug suspending amount of a pharmaceutically acceptable essential oil which is miscible with the propellant.
In another aspect of the invention there is provided the new use of a pharmaceutically acceptable essential oil to stabilise in a p MDI a suspension of a particulate drug in a pharmaceutically acceptable hydrofluoroalkane liquid in which the drug is insoluble and with which the essential oil is miscible.
In another aspect of the invention there is provided new use of a combination of a pharmaceutically acceptable hydrofluoroalkane liquid, a drug and a pharmaceutically acceptable essential oil in the manufacture of a composition for administration to the lung of an animal subject via inhalation, wherein the drug is in particulate form in the composition, the particles of drug are suspended in the hydrofluoroalkane liquid, the essential oil is miscible with the hydrofluoroalkane and the suspension is stabilised by the essential oil.
The hydrofluoroalkane liquid i n the composition is preferably selected from hydrofluoroalkane 227 and134a. The non -toxic essential oil used in the composition of the invention may generally be defined as a liquid which is substantially immiscible with water at room temperature, and is a liquid at room temperature. Essential oils are volatile oils comprised mainly of mono - and sesquiterpene hydrocarbons and their oxygen derivatives. They are products of distillation, expression or solvent extraction of plants, including flowers, lea ves, wood and grasses, or they may be produced synthetically. They comply with the European monograph for Essential Oils. The oil may be a single compound, or may be a mixture of compounds. The term "essential oils" is intended to include the following examples, though the invention is not limited to these examples: allspice berry, amber essence, anise seed, arnica, balsam of peru, basil, bay, bay leaf, bergamot, bois de rose (rosewood), cajeput, calendula (marigold pot), white camphor, caraway seed, car damon, carrot seed, cedarwood, celery, chamomile, chamomile, cinnamon, citronella, clary sage, clovebud, coriander, cumin, cypress, eucalyptus, fennel, Siberian fir needle, frankincense(olibanum oil), garlic, rose geranium, ginger, grapefruit, hyssop, jasmine, jojoba, juniper berry, lavender, lemon, lemongrass, lime, marjoram, mentol, mugwort, mullein flower, myrrh gum, bigarade neroli, nutmeg, bitter orange, sweet orange, oregano palmarosa, patchouly, pennyroyal, black pepper, peppermint, petite grain, pin e needle, poke root, rose absolute, rosehip seed, rosemary, sage, dalmation sage, sandalwood, sassafras, spearmint, spikenard, tangerine, tea tree, thuja (cedarleaf), thyme, vanilla extract, vetivert, wintergreen, witch hazel (hamamelia) extract, and ylang ylang (cananga) extract and isolated or synthesised components of these, such as 2,6 -dimethyl-2,4,6-octatriene; 4-propenylanisole; benzyl-3-phenylpropenoic acid; 1 ,7,7 -trimethylbicyclo[2.2.1]heptan -2-ol; 2,2- dimethyl-3-methylenebicyclo[2.2.1]heptane; 1 ,7, 7-trimethylbicyclo[2.2.1]heptane; trans-8-methyl-n-vanillyl-6-nonenamide; 2,2,5 -trimethylbicyclo[4.1.0]hept-5-ene; 5- isopropyl-2-methylphenol; p-mentha-6,8-dien-2-ol; p-mentha-6,8-dien-2-one;. beta- caryophyllene; 3-phenylpropenaldehyde; mixed geranial and neral; 3,7-dimethyl-6- octenal; 3,7-dimethyl-6-octen-l-ol; 4-allylanisole; ethyl-3 phenylpropenoic acid; 3 - ethoxy-4-hydroxybenzaldehyde; 1 ,8 -cineole; 4-allyl-2 methoxyphenol; 3,7,11 - trimethyl-2,6,10-dodecatrien-1-ol; 1 ,3,3-trimethylbicyclo[2.2.1]heptan -2-ol; 1 , 3,3- trimethylbicyclo[2.2.1]heptan -2-one; trans-3,7-dimethyl-2,6-octadien-1 -ol; trans-3,7- dimethyl-2,6-octadien-1-yl acetate; 3-methyl-2-(2 pentenyl)-2-cyclopenten-1-one; p- mentha-1 ,8-diene; 3,7-dimethyl-1 ,6-octadien-3-ol; 3,7-dimethyl-1 ,6-octadien-3-yl acetate; p-menthan-3-ol; p-menthan-3-one; methyl -2-aminobenzoate; methyl -3-oxo- 2-(2-pentenyl)-cyclopentane acetate; methyl -2-hydroxybenzoate; 7 -methyl-3- methylene-1 ,6-octadiene; cis-3,7-dimethyl-2,6-octadien-1ol; 2,6,6- trimethylbicyclo[3.1.1]hept -2-ene; 6,6-dimethyl-2-methylenebicyclo[3.1.1]heptane; p - menth-4-(8)-en-3-one; p-menth-1-en-4-ol; p-mentha-1 ,3-diene; p-menth-1 -en-8-ol; 2-isopropyl-5-methylphenol; citral; cinnamaldehyde and cineole.
Of these essential oils, those which are labeled as GRAS (Gen erally Regarded As Safe) for certain modes of application are particularly preferred. Although the oil used in the invention must be substantially immiscible with water, it is generally found to be useful for the oil to have some amphiphilic properties. The oil may comprise a relatively hydrophobic portion and a relatively hydrophilic portion. The hydrophobic portion generally comprises one or more C 6- 24-alkyl groups, preferably a single alkyl group, more preferably a C β-iβ alkyl group. A relatively hyd rophilic portion may, for instance, comprise a ketonic or aldehydic carbonyl group. Oils which have some amphiphilic character are believed to tend to localise at the surface of the particles of pharmaceutically active compound and act to stabilise their suspension in the hydrofluoroalkane.
In a preferred embodiment of the invention the oil is selected from citral, menthol, eucalyptus oil, cinnamaldehyde and cineole. Mixtures may be used.
The essential oils acts as a suspending agent. Its effect is to inhibit agglomeration of the drug particles in the suspension in liquefied HFA. The effect may be observed for instance by determining the particle size of suspended particles formed in the absence and in the presence of the essential oil. It may be possible to avoid the presence of all other additives which could affect the suspension, such as liquids like alcohols, glycols and esters, or surfactants or co - propellants.
Preferably the lever of other liquids is less than 20% by volume of the composition preferably less than 5% or less than 1 % by volume. In the preferred composition of the invention the volume ratio of essential oil to hydrofluoroalkane is in the range 1 to 10,000 to 10,000 to 1 , preferably in the range 1 to 100 to 1 to 2. The amount of essential oil may depend on the particle size and solids concentration of the active particles as well as the nature of the oil, the HFA and the active. It may be determined by the person skilled in the art.
The invention has two areas of utility, for two different classes of pharmaceutical active. The invention is of utility for formulating active compounds which are water soluble, that is have a water solubility of at least 0.1 mg/ml at room temperature. For example, it is of particular benefit for compounds which are sensitive to their environment and are formulated with solid protectants, e.g. lyoprotectants, such as a sugar. Sugars used as a lyoprotectant are generally selected from lactose and trehalose, but other sugars may also be used. The particles which are suspended in the liquid comprise both the protectant and the active. The particles themselves may be formed using the process of freeze -drying water-in-oil emulsions containing the pharmaceutical active and protectant in aqueous soluti on in the dispersed phase followed by washing. Alternatively, more conventional processing technologies for producing particles with desired characteristics (e.g. milling, precipitation, crystallization, polymerization, spray - drying, supercritical fluid p rocessing, solvent diffusion/evaporation, etc) may be employed.
In this aspect of the invention a water -soluble active is, for instance, a peptide or a protein, for instance an enzyme or a hormone, or a nucleic acid, for instance siRNA and DNA, such as ge ne therapy vectors and gene vaccines. The invention has been found to be of particular utility for formulating insulin. It is of particular utility for formulating proteins where the active particles comprise a protectant, preferably lactose. In this aspect of the invention the particles suspended in the composition have mean particle size in the range 0.01 to 20 μm preferably in the range 0.2 to 10 μm. Particles which are too large are deposited in the throat rather than reaching the lung. Particles which are too small may be exhaled.
The other type of active for which the invention has particular utility is for formulating relatively water-insoluble compounds. Such compounds may be defined as having water solubility less then 0.1 mg/ml at room tern perature. Such compounds should preferably have solubility in the stabiliser of at least 0.5 mg/ml at room temperature. Generally such compounds have solubility in the hydrofluoroalkane less than 0.1 mg/ml. Where the active has a higher solubility than this maximum in the hydrofluoroalkane, there should generally be no need for additional stabiliser and so the invention has little utility.
The relatively water-insoluble actives are often selected from steroids, corticosteroids, bronchodilators, beta -2 agonists, antibiotics, anti -microbials, antivirals, muscarinic antagonists, phosphodiesterase inhibitors and antihistamines. The invention is of utility for formulating an active selected from, for instance, salmeterol, terbutaline, cromolyns, beclometas one, budesonide, mometasone, ciclesonide, triamcinolone, fluticasone, rofleponide, salbutamol, formeterol, oxitropium, roflumilast and pharmaceutically acceptable salts and esters of any of these.
The composition should have a concentration of active se lected according to the therapeutic activity thereof and the volume dosage of composition usefully administered by the pMDI. A suitable unit dose administered via a pMDI contains 30 to 100 μl liquid composition. A suitable pharmaceutical active content f or such a dose is in the range 0.001 to 10 ιmg/100 μl, depending on the activity of the pharmaceutical agent, the age and weight of the patient etc. The person skilled in the art is generally able to select suitable concentrations for the invention. The invention allows stable compositions to be created having concentrations of up to 10 ιmg/100 μl active, allowing carefully controlled dosages to be delivered. For instance, a dose of composition administered per actuation of a pMDI contains in the range of 30 to 600 μg of pharmaceutical active per actuation. The essential oil may be used as the sole suspending agent in the composition. Its stabilising properties may allow other conventional components such as fixed oils (vegetable oils), alcohols, glycols, surfactants and polymers to be omitted from the compositions. The essential oil often prevents agglomeration of the drug particles to a sufficient degree to be used alone. Preferably the composition is substantially free of fixed oils, although small qu antities may present for instance as diluent for essential oil or as residue from an active as supplied. Preferably the level of fixed oils is less than 5% by volume, more preferably less than 1 % by volume.
Where polymer such as PVP is used as an additio nal suspending agent it is generally present in an amount in the range 0.01 to 5% w/v, preferably 0.1 to 2% w/v.
It is preferred to avoid administering alcohols and glycols and so the compositions are preferably substantially free of lower alcohols and gl ycols (C2-6), for instance containing less than 10% by volume, preferably less than 5% by volume, for instance less than 1 % by volume. It is also possible, by the use of essential oils in the invention, to avoid the inclusion of surfactants. However for some actives, the use of pharmaceutically acceptable surfactants may be provide additional control over the particle size or drug. For instance there may be surfactant used in the composition in an amount of 0.01 to 5% w/v, preferably less than 1 % w/v. M ost preferably the composition is substantially free of surfactant, that is there is less than 0.01 % w/v surfactant present.
There is also provided in the invention a method of producing the filled inhaler in which pharmaceutical active is dispersed into the suspension stabiliser to form a stabiliser dispersion, and the stabiliser dispersion is mixed with hydrofluoroalkane, usually in the device and under pressure.
Where the method is used for a pharmaceutical active which is soluble in the suspension s tabiliser, the active is dissolved into the suspension stabiliser to form a solution and the solution is added to the hydrofluoroalkane. Upon addition to the non-solvent for the therapeutic active (i.e. the hydrofluoroalkane), drug precipitate is formed. The presence of the suspension stabiliser maintains the particles of the precipitate in suspension.
Where the pharmaceutical active is insoluble in the suspension stabiliser, particles of the desired size for the final product are dispersed into the Ii quid suspension stabiliser, to form a stable suspension, and the suspension is then added to hydrofluoroalkane to form the stable final composition. In this embodiment the suspended particles may contain protectant which are generally sugars such as lactose and trehalose, and other appropriate excipients as well as active.
The present invention also encompasses novel compositions a) a pressurised composition for inhalation comprising a pharmaceutically acceptable hydrofluoroalkane liquid propellant, insul in in suspended particulate form and cineole and b) a pressurised composition inhalation for comprising a pharmaceutically acceptable hydrofluoroalkane liquid propellant, a steroid or corticosteroid for delivery to the lung and citral.
The invention is il lustrated in the worked examples. The results of some of the examples are illustrated in the figures as follows:
Figure 1 shows the particle size determination results on products of Example 1 ;
Figure 2 shows the effect on the aerolisation results by increasing oil concentration for products of the invention as described in Example 1 ; Figure 3 shows the variation of aerolisation results upon changing the concentration of active in the process as described in Example 1 ; Figures 4 and 5 show the resul ts of Example 2. Example 1
INSULIN-BASED COMPOSITIONS WITH CINEOLE STABILISER Insulin nanoparticles were prepared using an emulsion template method. 80 mg insulin and 20 mg lactose were dissolved into 1 ml of 0.1 M HCI. 2 g lecithin (phosphatidylcholin e surfactant) was weighed separately and dissolved in 7 ml chloroform to form the oily phase. The aqueous phase was added dropwise into the oil phase while homogenizing at low speed (10,000 rpm) followed by high speed homogenization (24,000 rpm) for 5 min. The emulsion formed was immediately snap-frozen using liquid nitrogen to immobilise the disperse phase. The frozen emulsions were transferred into a vacuum proof glass jar (Girovac Ltd., North Walsham, Norfolk, UK) and attached to the freeze -drier (Drywin ner 110, Heto- Holten A/S, Gydevang, Denmark) set at -1100C. Freeze-drying was performed for a minimum of 12 h to remove water from the frozen microscopic aqueous droplets. Following the freeze -drying stage, dry matter containing nanoparticles covered with surfactant (lecithin) was obtained. This was washed to remove lecithin by the following steps. The dry matter was suspended in 0.5% v/v triethylamine (TEA) in dichloromethane in which insulin and lactose were insoluble while lecithin was freely soluble, therefore preserving the structure of the nanoparticles. These nanoparticles were separated from free surfactant by centrifugation (3K30 Refrigerated centrifuge, Sigma Laborzentrifuges GmbH, Osterode am Harz, Germany). The sedimentation conditions were 17 ,000 rpm at 250C. 50 ml Oakridge Teflon (Trade Mark) centrifuge tubes (Nalge -Nunc Inc., Rochester, NY, USA) were selected for centrifugation owing to their excellent solvent compatibility and ease of nanoparticle collection from the non -stick surface. The solvent plus surfactants were decanted and the sediments which comprised nanoparticles were collected. The washing process was repeated twice.
The sediment of nanoparticles was suspended in 5 ml of dichloromethane and 0.25 ml cineole was added. The suspen sion formed was vortexed to ensure homogeneity. Dichloromethane was removed by evaporation under vacuum using a Rotavapor® (Bϋchi, Switzerland) set at 35 0C for 5 min. A paste of nanoparticles moistened by cineole was obtained which was subsequently cold fi Ned, oil placed in vials and cooled to a temperature below the boiling point of HFA 134a, then chilled (condensed) HFA 134a was added and the vial closed. The solid concentration (i.e. insulin plus lactose) of the filled vials was 1 % w/w.
Application of an anti-foaming agent to the emulsion (glyceryl monoleate) was investigated with an objective of reducing the size of the nanoparticles. This was achieved by dissolving 1 g of glyceryl monoleate and 2 g of lecithin in 7 ml of chloroform to form the oily ph ase. However, all other processing conditions were maintained as described above.
The formulation was subsequently assessed within two days of manufacture to determine the particle size using photon correlation spectroscopy (PCS), and the morphology of th e particles was examined using scanning electron microscopy (SEM). The formulations were also assessed for the integrity of insulin using gel permeation chromatography (GPC), high performance liquid chromatography (HPLC), circular dichroism and fluorescen ce spectroscopy.
Furthermore, aerolisation characterisation of the nanoparticles was carried out using a multistage liquid impinger (MSLI) set at 60L/min (effective cut -off diameters: stage 1 = 13 μm, stage 2 = 6.8 μm, stage 3 = 3.1 μm and stage 4 = 1.7 μm). The MSLI separates aerosol particles in a moving airstream on the basis of their aerodynamic diameters and allows an estimate of the fine particle fraction (FPF) of the aerosol emitted from a pMDI. In this work, FPF refers to the fraction of the inhaler output that has an aerodynamic diameter less than about 1.7 μm. This represents the fraction of the drug dose that can reach the alveolar region of the lung where systemic drug absorption occurs.
The PCS results for the product produced without glyceryl monooleate (Figure 1 ) indicate that the nanoparticles have a z -average diameter of around 550 nm with a narrow size distribution (polydispersity index 0.084 as determined by the PCS device). The SEM micrographs showed that the nanoparticles were substantially spherical in shape. The GPC and HPLC chromatograms, compared to standard insulin, show t hat the products are very similar to standard insulin, suggesting that insulin is not chemically degraded during the formulation process. Far-UV circular dichroism spectra indicate that the secondary structures of insulin are retained after processing. Th ere is no significant difference ( p<0.05) between spectra, and the secondary structure composition of unprocessed (control material) and processed (from the nanoparticles after delivery from the pMDI) were comparable. Control insulin, insulin from the n anoparticles after freeze -drying and insulin recovered following actuation of the pMDI formulation produced similar near -UV CD spectra, with a peak at around 275 nm. This indicates retention of tertiary structures of insulin after processing. This is con firmed from fluorescence spectra of insulin samples after delivery from the pMDI, and before and after de naturation with 6M guanidine hydrochloride, as compared with standard insulin under the same conditions. The tests on the aerolisation characteristics of the compositions show that there was an optimal stabiliser level. At concentrations of stabiliser which are too high, there may be an effect of reduction of the HFA evaporation from the spray plume, which leads to larger droplets with a high mass and consequently higher levels of deposition in the throat. With very low stabiliser concentrations, the nanoparticles are inadequately dispersed, possibly leading to aggregation and, again, higher levels of throat deposition. With a level of 0.25 ml stabili ser per batch the FPF improves. The results of three different levels of stabiliser are shown in Figure 2 which shows the effect of cineole concentration (ml/batch; a batch is equivalent to 100mg nanoparticle (insulin plus lactose) formulation in 1 Og HFA 134a) on FPF and throat deposition of nanoparticles.
Figure 3 shows the FPF and throat deposition of pMDI formulations containing 1 %, 2.5% and 5% concentration of insulin nanoparticles in HFA 134a each with cineole at a level of 0.25 ml/batch of 10 g HFA) .
It was also found that throat deposition decreased as the concentration of solid decreased, while FPF increased with decreasing solid concentration (Figure 3).
The size of the nanoparticles was reduced to z -average diameter of around 347 nm when glyceryl monoleate was added to the oil phase during the production of 1 % formulations of nanoparticles. These nanoparticles were used to formulate the optimized pMDI formulation.
Further studies were performed investigating the aerolisation of the optimized formulation. The emitted dose per actuation was approximately 0.55 mg total solids that yield 0.44 +/ - 0.04 mg/actuation insulin, based on the insulin content in the nanoparticles being 80%. The formulation had around 45% insulin weight of emitted dose (ex-actuator) delivered as FPF.
Example 2
SALMETEROL XINAFOATE (SX) -BASED COMPOSITIONS WITH CITRAL SUSPENDING AGENT
SX was weighed and dissolved in a known amount of chilled citral. SX has an aqueous solubility of 66 -81 μg/ml (Tong, HY, et al, Pharm. Res. (2001 ) 18, 852 - 858), i.e. it is not "water-soluble" in the terms of the present specification. The solution (see below for amount/concentration) was added dropwise in 10 ml of chilled HFA 134a while homogenizing at a lo w speed (10,000 rpm). A 63 μl actuation metering valve (Valois DF60 MK42; Valois, France) was immediately crimped onto the pMDI canister (using manual bottle crimper 3000, Aero -Tech Laboratory Equipment Company, USA). The amount of citral used was varied f rom 2 to 33% v/v while the SX concentration in the formulation was varied from 0.05 to 0.9% w/v based on the entire formulation. The pMDI vials were sonicated (XB6 Grant Instruments Ltd., UK) for approximately 1 min and the stability of the suspension was assessed visually. Formulations containing 0.05, 0.1 , 0.2, & 0.9% w/v SX and 2, 9 & 23% v/v citral were assessed for their aerosolisation characteristics using a two -stage (twin) impinger set at 60L/min (effective cut -off diameter between stages = 6.4 μm). The amount of SX in the upper and lower stage of the twin impinger was assessed using a high performance liquid chromatography (HPLC) set with the conditions outlined in Table 1. Table 1 : HPLC settings
Component Setting
Injection 20 μl volume
Flow rate 1 ml/min
Retention time ~ 2.2 min
Temperature 400C
UV detector 228 nm
Column Kromasil C18, ODS - 2 (5 Im, 250 mm x 4.6 mm id)
Mobile Phase Methanol:Acetonitrile:De -ionised water (30:30:40 v/v) containing 0.6% w/v ammonium a cetate and 0.2% w/v tetrabutylammonium
SX particles suspended in HFA134a were formed instantaneously when SX in citral solution was introduced to HFA 134a in all concentrations investigated as judged by observing the suspension in the sealed glass vials. Aerosolisation studies were carried out to show the effect of changing the drug concentration on drug deposited in the upper and lower stages with citral in an amount of 9% v/v . The results showed that the % w/w of drug deposited in the lower and upper s tages of twin impinger was not significantly different (p < 0.05) when formulations with different SX concentration were assessed (Figure 4). However, the amount of emitted dose increased with the increasing drug concentration in the formulation.
The effect of changing the citral concentration on the aerolisation of the formulations is shown in Figure 5 (using the 0.1 % SX composition). An increase in citral concentration in the formulation led to a decreased amount of SX (%w/w) deposited at the lower (FPF )stage of the twin impinger, whilst the amount of drug deposited in the upper stage of the impinger increased with increased citral in the formulation (Figure 5). The effective cut -off diameter between stages for the twin impinger is 6.4 μm, thus FPFs 64 μm in up to of 30% were demonstrated using this dispersion technique (Figures 4 and 5) with 2% v/v citral.

Claims

1 . A pressurised metered dose inhaler comprising a composition comprising a pharmaceutically acceptable hydrofluoroalkane liquid propellant, a drug to be delivered to the lung which is insoluble in the hydrofluoroalkane liquid, in particulate form, and a suspension stabiliser which is a pharmaceutically acceptable essential oil which is miscible with the hydrofluoroalkane liquid at room tempera ture.
2. An inhaler according to claim 1 , in which the particles containing drug also comprise a solid protectant, preferably a lyoprotectant, more preferably a sugar, most preferably selected from lactose and trehalose.
3. An inhaler according to cla im 1 or claim 2, in which the drug is a compound which is water-soluble, having water -solubility more than 0.1 mg/ml.
4. An inhaler according to claim 3, in which the drug is a peptide or a protein, preferably an enzyme or a hormone, more preferably insul in.
5. An inhaler according to claim 3 or claim 4, in which the particles have an average diameter in the range 0.01 to 20 μm.
6. An inhaler according to claim 1 , in which the drug is a compound having a water-solubility less than 0.1 mg/ml (room temper ature), a solubility in the stabiliser of at least 0.5 mg/ml (room temperature), and a solubility in the hydrofluoroalkane less than 0.1 mg/ml (room temperature).
7. An inhaler according to claim 6, in which the drug is selected from steroids, corticosteroids, bronchodilators, beta -2 agonists, antibiotics, antimicrobials, antivirals and antihistamines.
8. An inhaler according to claim 7, in which the drug is selected from salmeterol, terbutaline, cromolyn, beclometasone, budesonide, mometasone, ciclesonide, triamcinolone, fluticasone, rofleponide, salbutamol, formoterol, and pharmaceutically acceptable salts and esters thereof.
9. An inhaler according to any preceding claim, in which the oil is amphiphilic, and in which the hydrophobic portion comprise s at least one C6-24--alkyl chain, and the hydrophilic portion preferably comprises a ketonic or aldehydic carbonyl group.
10. An inhaler according to claim 9, in which the oil is selected from citral, menthol, eucalyptus oil, cinnamaldehyde and cineole.
1 1. An inhaler according to any preceding claim, in which the hydrofluoroalkane is HFA 134a or HFA 227.
12. An inhaler according to any of the preceding claims, in which the volume ratio of stabiliser to hydrofluoroalkane is in the range 1 :10,000 to 10,000:1 , preferably in the range 1 :100 to 1 :2.
13. An inhaler according to any preceding claim, which has a drug concentration in the range 0.001 to 10 % w/w based on the total composition.
14. An inhaler according to any preceding claim, adapted to deli ver a dose of composition containing drug in an amount in the range 0.001 to 10 mg drug per actuation.
15. A method of producing an inhaler according to claim 1 , in which drug is dispersed into the suspension stabiliser to form a dispersion, and the dispe rsion is added to hydrofluoroalkane to form a suspension, the suspension is put in a container and the container is closed in such a manner that the contents are pressurised at room temperature.
16. A method according to claim 15, in which the drug is soluble in the suspension stabiliser to an extent of no more than 0.1 mg/ml and is dispersed in the form of particles into the suspension stabiliser to form a suspension of the particles in the suspension stabiliser, and the suspension is combined with the hydrofluoroalkane.
17. A method according to claim 16, in which the particles contain a protectant as defined in claim 2.
18. A method according to claim 17, which comprises preliminary steps: forming an aqueous solution of drug and protectant; forming a water -in-oil emulsion of aqueous solution of drug and protectant into a continuous oil phase; and drying the emulsion to form particles.
19. A method according to claim 18, in which the emulsi on is dried by a spray-drying or lyophilisation process.
20. A method according to claim 15, in which the drug is soluble in the suspension stabiliser at a level of at least 0.5 mg/ml, wherein the drug is dissolved into the suspension stabiliser to form a solution and the solution is combined with the hydrofluoroalkane, whereby a drug precipitate is formed.
21. A method according to claim 15, in which the dispersion and the hydrofluoroalkane are mixed together under pressure in a container which is subsequently closed to form a pressurised metered dose inhaler.
22. A method according to claim 15, having the further feature(s) defined in any of claims 2 to 13.
23. A use of a pharmaceutically acceptable essential oil to stabilise in anMDI a suspension of a particulate drug in a pharmaceutically acceptable hydrofluoroalkane liquid in which the drug is insoluble and with which the essential oil is miscible.
24. A use of a combination of a pharmaceutically acceptable hydrofluoroalkane liquid, a drug and a pharmaceutically acceptable essential oil in the manufacture of a composition for administration to the lung of an animal subject via inhalation, wherein the drug is in particulate form in the composition, the particles of drug are suspended in the hydro fluoroalkane liquid, the essential oil is miscible with the hydrofluoroalkane and the suspension is stabilised by the essential oil.
25. Use according to claim 23 or 24, having the further features defined in any of claims 2 to 13.
26. A pressurised comp osition for inhalation comprising a pharmaceutically acceptable hydrofluoroalkane liquid propellant, insulin in suspended particulate form and cineole.
27. A pressurised composition inhalation for comprising a pharmaceutically acceptable hydrofluoroalkane liquid propellant, a steroid or corticosteroid for delivery to the lung and citral.
PCT/GB2007/050666 2006-10-31 2007-10-31 Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser WO2008053250A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/447,560 US20100143268A1 (en) 2006-10-31 2007-10-31 Formulations for Delivery Via Pressurised Metered Dose Inhalers Comprising an Essential Oil as Suspension Stabiliser
JP2009533962A JP2010508256A (en) 2006-10-31 2007-10-31 Formulations for delivery by pressurized dose metered inhalers
EP07824878A EP2089008B1 (en) 2006-10-31 2007-10-31 Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser
ES07824878T ES2373389T3 (en) 2006-10-31 2007-10-31 FORMULATIONS FOR ADMINISTRATION BY PRECISE DOSE PRESSURED INHALERS THAT INCLUDE AN ESSENTIAL OIL AS A STABILIZER OF SUSPENSION.
DK07824878.8T DK2089008T3 (en) 2006-10-31 2007-10-31 Formulations for delivery via pressurized metered dose inhalers comprising an essential oil as suspension stabilizer
AT07824878T ATE516800T1 (en) 2006-10-31 2007-10-31 FORMULATIONS FOR DELIVERY VIA PRESSURIZED DOSAGE AEROSOLS WITH AN ESSENTIAL OIL AS A SUSPENSION STABILIZER

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0621707.9 2006-10-31
GBGB0621707.9A GB0621707D0 (en) 2006-10-31 2006-10-31 Formulations for delivery via pressurised metered dose inhalers

Publications (2)

Publication Number Publication Date
WO2008053250A2 true WO2008053250A2 (en) 2008-05-08
WO2008053250A3 WO2008053250A3 (en) 2008-07-24

Family

ID=37547096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/050666 WO2008053250A2 (en) 2006-10-31 2007-10-31 Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser

Country Status (9)

Country Link
US (1) US20100143268A1 (en)
EP (2) EP2089008B1 (en)
JP (1) JP2010508256A (en)
AT (1) ATE516800T1 (en)
DK (1) DK2089008T3 (en)
ES (1) ES2373389T3 (en)
GB (1) GB0621707D0 (en)
PT (1) PT2089008E (en)
WO (1) WO2008053250A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9981092B2 (en) 2014-02-13 2018-05-29 Cardiff Scintigraphics Limited Pressurised metered dose inhalers and method of manufacture

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
EP3725311A1 (en) * 2014-02-10 2020-10-21 Respivant Sciences GmbH Methods for the treatment of lung diseases with mast cell stabilizers
US20150224077A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders
EP3256144B1 (en) 2015-02-13 2021-03-24 The Board of Trustees of the University of Illionis Peptide inhibition of ccr3-mediated diseases or conditions
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
JP2019531308A (en) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ Cromolyn composition for the treatment of pulmonary fibrosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
WO2001087268A1 (en) * 2000-05-19 2001-11-22 Generex Pharmaceuticals Inc. Micellar pharmaceutical compositions for buccal and pulmonary application
WO2002005785A1 (en) * 2000-07-18 2002-01-24 Aeropharm Technology Incorporated Modulated release therapeutic aerosols
WO2006036473A1 (en) * 2004-09-24 2006-04-06 3M Innovative Properties Company Medicinal aerosol formulations and methods of synthesizing ingredients therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
US6123924A (en) * 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
EP0655237A1 (en) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medicinal aerosol formulation
US5502076A (en) 1994-03-08 1996-03-26 Hoffmann-La Roche Inc. Dispersing agents for use with hydrofluoroalkane propellants
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
GB0015361D0 (en) 2000-06-22 2000-08-16 Pharmasol Ltd Improvements in pharmaceutical compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
WO2001087268A1 (en) * 2000-05-19 2001-11-22 Generex Pharmaceuticals Inc. Micellar pharmaceutical compositions for buccal and pulmonary application
WO2002005785A1 (en) * 2000-07-18 2002-01-24 Aeropharm Technology Incorporated Modulated release therapeutic aerosols
WO2006036473A1 (en) * 2004-09-24 2006-04-06 3M Innovative Properties Company Medicinal aerosol formulations and methods of synthesizing ingredients therefor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9981092B2 (en) 2014-02-13 2018-05-29 Cardiff Scintigraphics Limited Pressurised metered dose inhalers and method of manufacture
US11260185B2 (en) 2014-02-13 2022-03-01 Cardiff Scintigraphics Limited Pressurized metered dose inhalers and method of manufacture

Also Published As

Publication number Publication date
ES2373389T3 (en) 2012-02-03
PT2089008E (en) 2011-10-24
EP2364696A1 (en) 2011-09-14
DK2089008T3 (en) 2011-10-24
WO2008053250A3 (en) 2008-07-24
EP2089008A2 (en) 2009-08-19
ATE516800T1 (en) 2011-08-15
US20100143268A1 (en) 2010-06-10
GB0621707D0 (en) 2006-12-13
EP2089008B1 (en) 2011-07-20
JP2010508256A (en) 2010-03-18

Similar Documents

Publication Publication Date Title
EP2089008B1 (en) Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser
AU2002313828B2 (en) Pharmaceutical compositions for the treatment of asthma
TWI546094B (en) Compositions for respiratory delivery of active agents and associated methods and systems
AU729966B2 (en) Pharmaceutical aerosol composition
CA2352483C (en) Pharmaceutical aerosol composition containing hfa 227 and hfa 134a
AU2002211311B2 (en) Medicinal aerosol formulations
US20040062720A1 (en) Pharmaceutical aerosol composition
AU2002313828A1 (en) Pharmaceutical compositions for the treatment of asthma
US20090246149A1 (en) Medicinal aerosol formulations
AU2002211311A1 (en) Medicinal aerosol formulations
US20100095963A1 (en) Pharmaceutical compositions
EP1785156B1 (en) Metered dose inhaler containing an aerosol suspension formulation
CH627075A5 (en) Inhalation composition comprising a dispersion or suspension of a medicament to be inhaled
JPH05148185A (en) Preparation of aerosol composition
AU774250B2 (en) Pharmaceutical aerosol composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824878

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009533962

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007824878

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12447560

Country of ref document: US